

# Tatsuki Fukami

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8337862/tatsuki-fukami-publications-by-citations.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132  
papers

4,280  
citations

36  
h-index

58  
g-index

134  
ext. papers

4,846  
ext. citations

4.3  
avg, IF

5.45  
L-index

#	Paper	IF	Citations
132	Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 1759-68	4	190
131	Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 282-97	6.1	175
130	A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2015</b> , 30, 30-51	2.2	147
129	Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans. <i>Journal of Lipid Research</i> , <b>2016</b> , 57, 2130-2137	6.3	144
128	The emerging role of human esterases. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2012</b> , 27, 466-77	2.2	144
127	Human CYP2E1 is regulated by miR-378. <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 1045-52	6	133
126	MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 4415-22	5.4	119
125	Human CYP2A6 is induced by estrogen via estrogen receptor. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 1935-41	4	109
124	PPAR $\alpha$ s regulated by miR-21 and miR-27b in human liver. <i>Pharmaceutical Research</i> , <b>2011</b> , 28, 2467-76	4.5	102
123	Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. <i>Toxicology and Applied Pharmacology</i> , <b>2013</b> , 272, 154-60	4.6	91
122	Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. <i>Biochemical Pharmacology</i> , <b>2011</b> , 82, 1747-56	6	78
121	Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e30250	3.7	74
120	Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. <i>European Journal of Pharmaceutical Sciences</i> , <b>2004</b> , 22, 419-25	5.1	67
119	In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 2173-8	4	65
118	A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. <i>Clinical Pharmacology and Therapeutics</i> , <b>2004</b> , 76, 519-27	6.1	65
117	Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 911-20	1.9	64
116	Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1103-9	4	62

115	Human arylacetamide deacetylase is a principal enzyme in flutamide hydrolysis. <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 1513-20	4	60
114	Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. <i>Chemical Research in Toxicology</i> , <b>2008</b> , 21, 720-5	4	60
113	Halothane-induced liver injury is mediated by interleukin-17 in mice. <i>Toxicological Sciences</i> , <b>2009</b> , 111, 302-10	4.4	56
112	CYP2A13 expressed in human bladder metabolically activates 4-aminobiphenyl. <i>International Journal of Cancer</i> , <b>2006</b> , 119, 2520-6	7.5	56
111	Involvement of immune-related factors in diclofenac-induced acute liver injury in mice. <i>Toxicology</i> , <b>2012</b> , 293, 107-114	4.4	53
110	A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 4873-4884	5.4	52
109	Arylacetamide deacetylase is a determinant enzyme for the difference in hydrolase activities of phenacetin and acetaminophen. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 1532-7	4	49
108	CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. <i>Drug Metabolism and Disposition</i> , <b>2005</b> , 33, 1811-8	4	48
107	Comparison of substrate specificity among human arylacetamide deacetylase and carboxylesterases. <i>European Journal of Pharmaceutical Sciences</i> , <b>2015</b> , 78, 47-53	5.1	47
106	Species differences in tissue distribution and enzyme activities of arylacetamide deacetylase in human, rat, and mouse. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 671-9	4	47
105	Metabolic activation and inflammation reactions involved in carbamazepine-induced liver injury. <i>Toxicological Sciences</i> , <b>2012</b> , 130, 4-16	4.4	46
104	Effects of silver nanoparticles on rat hepatic cytochrome P450 enzyme activity. <i>Xenobiotica</i> , <b>2012</b> , 42, 854-62	2	46
103	Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. <i>Drug Metabolism and Disposition</i> , <b>2005</b> , 33, 1202-10	4	46
102	A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. <i>Biochemical Pharmacology</i> , <b>2005</b> , 70, 801-8	6	43
101	Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 1388-95	4	42
100	Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1389-97	4	41
99	A novel duplication type of CYP2A6 gene in African-American population. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 515-20	4	41
98	CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 335-9	4	37

97	Novel human CYP2A6 alleles confound gene deletion analysis. <i>FEBS Letters</i> , <b>2004</b> , 569, 75-81	3.8	37
96	Aryl hydrocarbon receptor nuclear translocator in human liver is regulated by miR-24. <i>Toxicology and Applied Pharmacology</i> , <b>2012</b> , 260, 222-31	4.6	36
95	Retinoid X receptor $\beta$ in human liver is regulated by miR-34a. <i>Biochemical Pharmacology</i> , <b>2014</b> , 90, 179-87	6	35
94	Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. <i>Biochemical Pharmacology</i> , <b>2011</b> , 81, 289-94	6	35
93	Prilocaine- and lidocaine-induced methemoglobinemia is caused by human carboxylesterase-, CYP2E1-, and CYP3A4-mediated metabolic activation. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1220-30	4	33
92	An in vitro drug-induced hepatotoxicity screening system using CYP3A4-expressing and gamma-glutamylcysteine synthetase knockdown cells. <i>Toxicology in Vitro</i> , <b>2010</b> , 24, 1032-8	3.6	33
91	CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 703-12	4	32
90	IL-4 mediates dicloxacillin-induced liver injury in mice. <i>Toxicology Letters</i> , <b>2011</b> , 200, 139-45	4.4	32
89	Contributions of arylacetamide deacetylase and carboxylesterase 2 to flutamide hydrolysis in human liver. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 1080-4	4	32
88	RNA Editing Modulates Human Hepatic Aryl Hydrocarbon Receptor Expression by Creating MicroRNA Recognition Sequence. <i>Journal of Biological Chemistry</i> , <b>2016</b> , 291, 894-903	5.4	31
87	Evaluation and mechanistic analysis of the cytotoxicity of the acyl glucuronide of nonsteroidal anti-inflammatory drugs. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1-8	4	31
86	Human UDP-glucuronosyltransferase isoforms involved in haloperidol glucuronidation and quantitative estimation of their contribution. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 240-8	4	30
85	CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-based screening assay. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 838-46	4	30
84	Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 1345-52	4	29
83	Epigenetic regulation is a crucial factor in the repression of UGT1A1 expression in the human kidney. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1738-43	4	28
82	Interleukin-17 is involved in alpha-naphthylisothiocyanate-induced liver injury in mice. <i>Toxicology</i> , <b>2010</b> , 275, 50-7	4.4	28
81	Transcriptional regulation of human carboxylesterase 1A1 by nuclear factor-erythroid 2 related factor 2 (Nrf2). <i>Biochemical Pharmacology</i> , <b>2010</b> , 79, 288-95	6	28
80	Human arylacetamide deacetylase hydrolyzes ketoconazole to trigger hepatocellular toxicity. <i>Biochemical Pharmacology</i> , <b>2016</b> , 116, 153-61	6	27

79	Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. <i>Biochemical Pharmacology</i> , <b>2014</b> , 87, 660-7	6	27
78	Preparation of a specific monoclonal antibody against human UDP-glucuronosyltransferase (UGT) 1A9 and evaluation of UGT1A9 protein levels in human tissues. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 1620-7	4	27
77	Th2 cytokine-mediated methimazole-induced acute liver injury in mice. <i>Journal of Applied Toxicology</i> , <b>2012</b> , 32, 823-33	4.1	27
76	Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog. <i>Drug Metabolism and Disposition</i> , <b>2016</b> , 44, 409-16	4	26
75	Carbamazepine-Induced Liver Injury Requires CYP3A-Mediated Metabolism and Glutathione Depletion in Rats. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 958-68	4	26
74	Human $\beta$ -hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 9240-9	5.4	26
73	Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner. <i>Drug Metabolism and Disposition</i> , <b>2011</b> , 39, 2057-65	4	25
72	Difference in substrate specificity of carboxylesterase and arylacetamide deacetylase between dogs and humans. <i>European Journal of Pharmaceutical Sciences</i> , <b>2018</b> , 111, 167-176	5.1	24
71	Isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 337-44	2.9	24
70	Single-Nucleotide Polymorphisms in Cytochrome P450 2E1 (CYP2E1) 3'Untranslated Region Affect the Regulation of CYP2E1 by miR-570. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 1450-7	4	23
69	Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. <i>Toxicology Letters</i> , <b>2014</b> , 228, 13-24	4.4	23
68	P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3133-45	12.9	23
67	Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2014</b> , 29, 333-40	2.2	23
66	Estradiol and progesterone modulate halothane-induced liver injury in mice. <i>Toxicology Letters</i> , <b>2011</b> , 204, 17-24	4.4	23
65	Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. <i>Journal of Toxicological Sciences</i> , <b>2012</b> , 37, 931-42	1.9	23
64	Regulation of cytochrome b5 expression by miR-223 in human liver: effects on cytochrome P450 activities. <i>Pharmaceutical Research</i> , <b>2014</b> , 31, 780-94	4.5	22
63	Involvement of Th2 cytokines in the mouse model of flutamide-induced acute liver injury. <i>Journal of Applied Toxicology</i> , <b>2012</b> , 32, 815-22	4.1	22
62	A novel mouse model for phenytoin-induced liver injury: involvement of immune-related factors and P450-mediated metabolism. <i>Toxicological Sciences</i> , <b>2013</b> , 136, 250-63	4.4	22

61	Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. <i>Toxicology in Vitro</i> , <b>2009</b> , 23, 1179-87	3.6	22
60	Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development. <i>Hepatology Communications</i> , <b>2018</b> , 2, 1567-1582	6	22
59	Identification of enzymes responsible for nitrazepam metabolism and toxicity in human. <i>Biochemical Pharmacology</i> , <b>2017</b> , 140, 150-160	6	21
58	Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. <i>Archives of Toxicology</i> , <b>2011</b> , 85, 199-207	5.8	21
57	Knockdown of superoxide dismutase 2 enhances acetaminophen-induced hepatotoxicity in rat. <i>Toxicology</i> , <b>2009</b> , 264, 89-95	4.4	21
56	A novel polymorphic allele of human arylacetamide deacetylase leads to decreased enzyme activity. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 1183-90	4	21
55	Mechanism of exacerbative effect of progesterone on drug-induced liver injury. <i>Toxicological Sciences</i> , <b>2012</b> , 126, 16-27	4.4	20
54	Involvement of immune- and inflammatory-related factors in flucloxacillin-induced liver injury in mice. <i>Journal of Applied Toxicology</i> , <b>2015</b> , 35, 142-51	4.1	19
53	Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury. <i>Biochemical Pharmacology</i> , <b>2018</b> , 151, 69-78	6	18
52	Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury. <i>Toxicology Letters</i> , <b>2014</b> , 224, 215-24	4.4	18
51	Editor's Highlight: Farnesoid X Receptor Protects Against Low-Dose Carbon Tetrachloride-Induced Liver Injury Through the Taurocholate-JNK Pathway. <i>Toxicological Sciences</i> , <b>2017</b> , 158, 334-346	4.4	16
50	Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 812-8	4	16
49	Involvement of miRNAs in the early phase of halothane-induced liver injury. <i>Toxicology</i> , <b>2014</b> , 319, 75-84	4.4	16
48	Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries. <i>Toxicology and Applied Pharmacology</i> , <b>2012</b> , 264, 42-50	4.6	16
47	Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. <i>Journal of Applied Toxicology</i> , <b>2016</b> , 36, 35-47	4.1	16
46	Metabolic activation by human arylacetamide deacetylase, CYP2E1, and CYP1A2 causes phenacetin-induced methemoglobinemia. <i>Biochemical Pharmacology</i> , <b>2012</b> , 84, 1196-206	6	15
45	Terbinafine stimulates the pro-inflammatory responses in human monocytic THP-1 cells through an ERK signaling pathway. <i>Life Sciences</i> , <b>2010</b> , 87, 537-44	6.8	15
44	Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 761-72	1.9	15

43	Substrate selectivity of human aldehyde oxidase 1 in reduction of nitroaromatic drugs. <i>Archives of Biochemistry and Biophysics</i> , <b>2018</b> , 659, 85-92	4.1	15
42	Indiplon is hydrolyzed by arylacetamide deacetylase in human liver. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 751-8	4	14
41	An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 2109-16	4	14
40	P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. <i>Molecular Pharmaceutics</i> , <b>2015</b> , 12, 3714-23 <sup>5,6</sup>	5.6	13
39	Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 1034-1039	3.5	13
38	Immunohistochemical analysis of CYP2A13 in various types of human lung cancers. <i>Cancer Science</i> , <b>2010</b> , 101, 1024-8	6.9	13
37	A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production. <i>Biochemical Pharmacology</i> , <b>2015</b> , 98, 659-70	6	11
36	Stimulation of human monocytic THP-1 cells by metabolic activation of hepatotoxic drugs. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2012</b> , 27, 621-30	2.2	11
35	Methylation of adenosine at the N position post-transcriptionally regulates hepatic P450s expression. <i>Biochemical Pharmacology</i> , <b>2020</b> , 171, 113697	6	11
34	Quantitative Analysis of UDP-Glucuronosyltransferase Ugt1a and Ugt2b mRNA Expression in the Rat Liver and Small Intestine: Sex and Strain Differences. <i>Drug Metabolism and Disposition</i> , <b>2019</b> , 47, 38-44	4	10
33	miR-141-3p commonly regulates human UGT1A isoforms via different mechanisms. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2018</b> , 33, 203-210	2.2	10
32	Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. <i>Experimental and Toxicologic Pathology</i> , <b>2016</b> , 68, 27-38		9
31	In vitro approach to elucidate the relevance of carboxylesterase 2 and N-acetyltransferase 2 to flupirtine-induced liver injury. <i>Biochemical Pharmacology</i> , <b>2018</b> , 155, 242-251	6	9
30	Changes in the expression of miRNAs at the pericentral and periportal regions of the rat liver in response to hepatocellular injury: comparison with the changes in the expression of plasma miRNAs. <i>Toxicology</i> , <b>2014</b> , 322, 89-98	4.4	9
29	RNA Editing Enzymes Modulate the Expression of Hepatic CYP2B6, CYP2C8, and Other Cytochrome P450 Isoforms. <i>Drug Metabolism and Disposition</i> , <b>2019</b> , 47, 639-647	4	8
28	Characterization of Species Differences in Tissue Diltiazem Deacetylation Identifies Ces2a as a Rat-Specific Diltiazem Deacetylase. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 1218-25	4	8
27	N-Glycosylation during translation is essential for human arylacetamide deacetylase enzyme activity. <i>Biochemical Pharmacology</i> , <b>2014</b> , 87, 352-9	6	8
26	Strain and sex differences in drug hydrolase activities in rodent livers. <i>European Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 142, 105143	5.1	8

25	Evaluation of expression and glycosylation status of UGT1A10 in Supersomes and intestinal epithelial cells with a novel specific UGT1A10 monoclonal antibody. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 1027-1034	4	7
24	Role of Human Arylacetamide Deacetylase (AADAC) on Hydrolysis of Eslicarbazepine Acetate and Effects of Genetic Polymorphisms on Hydrolase Activity. <i>Drug Metabolism and Disposition</i> , <b>2021</b> , 49, 322-329	4	6
23	SLC35B1 significantly contributes to the uptake of UDPGA into the endoplasmic reticulum for glucuronidation catalyzed by UDP-glucuronosyltransferases. <i>Biochemical Pharmacology</i> , <b>2020</b> , 175, 1139-1146	6	4
22	Adenosine Deaminases Acting on RNA Downregulate the Expression of Constitutive Androstane Receptor in the Human Liver-Derived Cells by Attenuating Splicing. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 370, 408-415	4.7	4
21	The N-methyladenosine modification posttranscriptionally regulates hepatic UGT2B7 expression. <i>Biochemical Pharmacology</i> , <b>2021</b> , 189, 114402	6	4
20	Quantitative analysis of mRNA expression levels of aldo-keto reductase and short-chain dehydrogenase/reductase isoforms in human livers. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 35, 539-547	2.2	3
19	Non-P450 Drug-Metabolizing Enzymes: Contribution to Drug Disposition, Toxicity, and Development. <i>Annual Review of Pharmacology and Toxicology</i> , <b>2021</b> ,	17.9	3
18	Arylacetamide deacetylase as a determinant of the hydrolysis and activation of abiraterone acetate in mice and humans. <i>Life Sciences</i> , <b>2021</b> , 284, 119896	6.8	3
17	mA modification impacts hepatic drug and lipid metabolism properties by regulating carboxylesterase 2. <i>Biochemical Pharmacology</i> , <b>2021</b> , 193, 114766	6	3
16	Hepatic Dipeptidyl Peptidase-4 Controls Pharmacokinetics of Vildagliptin In Vivo. <i>Drug Metabolism and Disposition</i> , <b>2017</b> , 45, 237-245	4	2
15	Role of cytochrome P450-mediated metabolism and identification of novel thiol-conjugated metabolites in mice with phenytoin-induced liver injury. <i>Toxicology Letters</i> , <b>2015</b> , 232, 79-88	4.4	2
14	A Novel Systematic Approach for Selection of Prodrugs Designed to Improve Oral Absorption. <i>Journal of Pharmaceutical Sciences</i> , <b>2020</b> , 109, 1736-1746	3.9	2
13	Hydrolase activities of cynomolgus monkey liver microsomes and recombinant CES1, CES2, and AADAC. <i>European Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 161, 105807	5.1	2
12	Identification of an isoform catalyzing the CoA conjugation of nonsteroidal anti-inflammatory drugs and the evaluation of the expression levels of acyl-CoA synthetases in the human liver. <i>Biochemical Pharmacology</i> , <b>2021</b> , 183, 114303	6	2
11	Differences in Hydrolase Activities in the Liver and Small Intestine between Marmosets and Humans. <i>Drug Metabolism and Disposition</i> , <b>2021</b> , 49, 718-728	4	1
10	Human superoxide dismutase 1 attenuates quinoneimine metabolite formation from mefenamic acid. <i>Toxicology</i> , <b>2021</b> , 448, 152648	4.4	1
9	Epicatechin gallate and epigallocatechin gallate are potent inhibitors of human arylacetamide deacetylase. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2021</b> , 39, 100397	2.2	1
8	PPAR $\gamma$ regulates the expression of human arylacetamide deacetylase involved in drug hydrolysis and lipid metabolism.. <i>Biochemical Pharmacology</i> , <b>2022</b> , 115010	6	1



7	Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2019</b> , 34, 280-286	2.2	○
6	Decrease in ADAR1 expression by exposure to cigarette smoke enhances susceptibility to oxidative stress. <i>Toxicology Letters</i> , <b>2020</b> , 331, 22-32	4.4	○
5	Pirfenidone 5-hydroxylation is mainly catalysed by CYP1A2 and partly catalysed by CYP2C19 and CYP2D6 in the human liver. <i>Xenobiotica</i> , <b>2021</b> , 1-8	2	○
4	Arylacetamide deacetylase knockout mice are sensitive to ketoconazole-induced hepatotoxicity and adrenal insufficiency. <i>Biochemical Pharmacology</i> , <b>2021</b> , 195, 114842	6	○
3	Identification of miRNAs that regulate human CYP2B6 expression. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2021</b> , 38, 100388	2.2	○
2	Adenosine deaminases acting on RNA modulate the expression of the human pregnane X receptor. <i>Drug Metabolism and Pharmacokinetics</i> , <b>2021</b> , 37, 100367	2.2	○
1	Systematic Approach for Screening of Prodrugs: Evaluation Using Oseltamivir Analogues as Models. <i>Journal of Pharmaceutical Sciences</i> , <b>2021</b> , 110, 925-934	3.9	○